博睿康正式启动科创板IPO：或与强脑科技争夺「中国脑机接口第一股」

Group 1 - The core viewpoint of the article is that 博睿康 (Borui Kang) is set to become the first company in China to launch a listed implantable brain-machine interface product, with its IPO process officially starting on February 4, 2026 [3][4]. - 博睿康 was founded in 2011 and has a core team from Tsinghua University's top neural engineering laboratory, focusing on the research, development, production, and sales of brain-machine interface systems [3][4]. - The NEO brain-machine interface product, developed in collaboration with Tsinghua University, has successfully completed its first implantation at Capital Medical University and has shown significant results in feasibility trials across multiple hospitals [4]. Group 2 - The NEO project is expected to submit a Class III innovative medical device registration application to the National Medical Products Administration, aiming to be the first listed implantable brain-machine interface product in China [4]. - The founder and chief engineer of 博睿康, 胥红, mentioned that the NEO 1.0 version is being registered, while the 2.0 version will include additional features such as language and limb decoding, targeting more minimally invasive, higher throughput, and lower cost solutions [4]. - 博睿康 has received investments from various institutions, including Sequoia China, K2VC, and others, indicating strong financial backing for its innovative projects [5].